Current BTLA-directed interventions face limitations in efficacy, patient selection, and safety, partly due to the heterogeneous expression of BTLA across tumor types and immune cell subsets, as well as the complexity of its bidirectional signaling with HVEM [4,84]. Here, BTLA is linked to neoplasm.